GMP– tag –
-
Texas Children’s Hospital Establishes Cell and Gene Therapy Innovation Hub to Accelerate Development and Expand Access
Texas Children's Hospital USA Overview Texas Children's Hospital has established a new innovation hub to accelerate breakthroughs in cell and gene therapy (CGT). This comprehensive facility centralizes all necessary resources and experti... -
CGT Manufacturers Transform Regulatory Demands into Innovation Drivers: New Strategies for Enhanced Quality and Efficiency
MasterControl USA Overview Cell and gene therapy (CGT) manufacturers are adopting new strategies to leverage stringent regulatory requirements as opportunities for innovation and quality improvement, rather than mere obstacles. Central t... -
China’s First Approved MSC Therapy, Ruibosheng, Launched at Fraction of Global Price, Receives Conditional Approval for Severe GVHD
BioInformant China Overview China's first approved mesenchymal stem cell (MSC) therapy, Ruibosheng, has been launched at a fraction of global pricing, having received conditional approval from the NMPA on January 2, 2025. Approved for st... -
Liv Hospital Accelerates iPSC Therapy with Bioreactor Investment, Targeting Parkinson’s Disease
Liv Hospital Turkey Overview Liv Hospital is addressing the critical challenge of safe and efficient mass production of induced pluripotent stem cells (iPSCs) through a major investment in advanced bioreactor systems. This initiative aim... -
Porton Advanced Secures China NMPA Commercial Manufacturing License for CGT Products, Expanding CDMO Services from Process Development to Commercialization
Contract Pharma China Overview Porton Advanced has obtained a Class C drug manufacturing license from China's National Medical Products Administration (NMPA), enabling it to provide commercial contract manufacturing services for cell and... -
Catalent Expands AAV Gene Therapy Partnership with Taysha Gene Therapies, Securing Exclusive Commercial Manufacturing for Rett Syndrome Treatment TSHA-102
Pharma Manufacturing USA Overview Taysha Gene Therapies and CDMO Catalent have expanded their strategic partnership, designating Catalent as the exclusive commercial manufacturer for TSHA-102, an AAV-based gene therapy for Rett syndrome,... -
RoosterBio and Applied StemCell Partner to Scale iPSC-Based Bioprocess Solutions, Accelerating Cell Therapy Manufacturing
MD Tech Council (Facebook) USA Overview RoosterBio and Applied StemCell have formed a strategic partnership to scale iPSC-based bioprocess solutions, aiming to accelerate the commercial production of cell therapies. This collaboration in... -
EUDA Health Partners with GO POSB and SIIT to Accelerate Off-the-Shelf iPSC Cell Therapy for Oncology and Wellness
Stock Titan Singapore Overview EUDA Health announced a collaboration to integrate GO POSB's iPSC platform with SIIT's NK and NK-TCR cell engineering capabilities, aiming to advance off-the-shelf cell therapy programs in oncology and well... -
Capra Biosciences Boosts Domestic Manufacturing of Essential Medicines with Continued HHS Support, Strengthening Biopharmaceutical Supply Chain Resilience
BioSpace USA Overview Capra Biosciences announced plans to strengthen its domestic manufacturing capabilities for essential medicines with ongoing financial support from the U.S. Department of Health and Human Services (HHS). This initia... -
NueCell Bio Launches as Translational Partner to Accelerate Cell Therapies from Discovery to GMP Manufacturing
PR Newswire USA Overview NueCell Bio has officially launched as a new "translational partner" dedicated to accelerating cell therapy products from scientific discovery through GMP-compliant manufacturing and clinical readiness. The compa...
